Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma

医学 四分位间距 彭布罗利珠单抗 内科学 脊索瘤 完全响应 进行性疾病 无容量 肿瘤科 实体瘤疗效评价标准 胃肠病学 外科 疾病 免疫疗法 化疗 癌症
作者
Andrew Justin Bishop,Behrang Amini,Heather Yan Lin,Shaan Mohammed Raza,SHREYASKUMAR R. PATEL,David R. Grosshans,Amol Jitendra Ghia,Ahsan Saleem Farooqi,B. Ashleigh Guadagnolo,Devarati Mitra,Kadir Caner Akdemir,Alexander J. Lazar,Wei‐Lien Wang,Christopher A Alvarez-Breckenridge,Justin E. Bird,Laurence D. Rhines,Neeta Somaiah,Anthony Paul Conley
出处
期刊:Journal of Immunotherapy [Lippincott Williams & Wilkins]
卷期号:45 (8): 374-378 被引量:33
标识
DOI:10.1097/cji.0000000000000431
摘要

The aim of this study is to evaluate the outcomes and tolerance of immune checkpoint inhibitors (ICIs) for patients with recurrent chordoma. We reviewed the records of 17 patients with recurrent chordomas who received ICIs for progressing disease as part of their treatment between 2016 and 2020. Response was assessed using response evaluation criteria in solid tumors 1.1 criteria. The Kaplan-Meier method was used to estimate the duration of response, progression-free survival (PFS), and overall survival (OS). Clinical benefit was defined as having stable disease (SD), a partial response, or a complete response. The median follow-up from the start of ICIs was 29 months [interquartile range (IQR): 13-35 m]. The majority received pembrolizumab (n=9, 53%), and the median number of cycles delivered was 8 (IQR: 7-12). The 1-year OS was 87%, and the 1-year PFS was 56% with a median PFS of 14 months (95% CI, 5-17 mo). After ICI initiation, most patients (n=15, 88%) had clinical benefit consisting of a complete response (n=1, 6%), partial response (n=3, 18%), and stable disease (n=11, 65%). Among all responders (n=15), the median duration of response was 12 months. Toxicities were limited: 2 (12%) patients having grade 3/4 immune-related toxicities (colitis, grade 3; myocarditis, grade 4). We observed a high rate of clinical benefit and favorable durability from ICI use for patients with recurrent chordoma. These data provide support for the integration of ICIs as a standard first-line systemic therapy option for patients with recurrent chordoma. Prospective studies are warranted to further evaluate efficacy and enhance response rates.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
CodeCraft的应助被rose采纳,获得10
1秒前
领导范儿的应助被嗷嗷ao采纳,获得10
2秒前
crystal完成签到,获得积分10
2秒前
Wenlia完成签到,获得积分10
2秒前
wangyuu发布了新的文献求助10
3秒前
123完成签到 ,获得积分10
3秒前
ding完成签到,获得积分10
3秒前
4秒前
wyl完成签到,获得积分10
4秒前
xiang发布了新的文献求助10
5秒前
明亮的忆枫完成签到,获得积分10
6秒前
6秒前
清辉影给漫漫的求助进行了留言
6秒前
Firsterchao的应助被元谷雪采纳,获得10
7秒前
只因发布了新的文献求助10
7秒前
华仔的应助被哈哈采纳,获得10
7秒前
斯文败类的应助被迅速的不评采纳,获得10
8秒前
CipherSage的应助被Yaoz采纳,获得30
8秒前
8秒前
小狮子完成签到,获得积分10
8秒前
9秒前
木头发布了新的文献求助10
9秒前
9秒前
9秒前
许右发布了新的文献求助10
10秒前
haha发布了新的文献求助10
10秒前
科研通AI6.3的应助被杨淼采纳,获得10
11秒前
11秒前
激动的元瑶完成签到 ,获得积分10
12秒前
12秒前
研雾完成签到,获得积分10
13秒前
maoqiuzhao发布了新的文献求助10
14秒前
molihuakai的应助被文献互助1采纳,获得10
14秒前
bkagyin的应助被rose采纳,获得10
14秒前
maoamo2024发布了新的文献求助10
15秒前
yu完成签到,获得积分10
15秒前
田様的应助被路小雨采纳,获得10
15秒前
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621